Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer

Lv, Rongbin; Wang, Qinggang; Liu, Chao; Liu, Fang; Zhao, Qing; Jin, Han; Liu, Bin; Li, Cheng-Li

doi:10.2147/ott.s135145

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously it was considered that high-dose of Iodine-131 is appropriate for complete ablation of micro-metastasis and low-dose may not sufficiently serve the purpose however multiple research studies conducted in last 2 decades to assess the role of low-dose RAI in successful ablation have concluded that there was not much difference in successful ablation with low-dose in comparison to high-dose treatment, moreover low-dose was associated with low prevalence of adverse effects. 15 A clinical research study by Muzzaferi and Kloos in 2001 4 revealed that there was no difference in recurrence rates (4 and 6%, respectively at P = .1) between lowactivity (1037-1850 MBq) and high-activity (1887-7400 MBq) Iodine-131 remnant ablation group. Although low recurrence rate is reported with high RAI dose yet low-dose therapy is associated with additional benefits of short hospital-stay, less adverse effects, and cost-effectiveness.…”

Section: Discussionmentioning

confidence: 95%

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience

et al. 2021

View full text Add to dashboard Cite

The role of Iodine-131 therapy is well established as an adjuvant therapy and for thyroid remnant ablation in differentiated thyroid cancer (DTC); however controversy still exists regarding its appropriate dose. Purpose of this study was to compare the effectiveness of low-dose and high-dose Iodine-131 ablation therapies in low- and intermediate-risk PTC patients. Eighty-four patients were divided equally into Group I: Ablated with high dose of Iodine-131 and Group II: Ablated with low dose of Iodine-131. Iodine-131 WBS, serum TG levels and USG neck of all patients were performed at first presentation, 6 months, 1 year, and 2 years follow up. Results are as follows: Group I: 64%, 72%, and 76% intermediate-risk patients were disease free at the follow up intervals of 6 months, 1 year, and 2 years, respectively. Similarly 70%, 82%, and 82% low-risk patients were disease free at above mentioned intervals. Group II: 56%, 60%, and 64% were disease free among intermediate-risk patients while percentage of disease free low-risk patients was 70%, 76%, and 76% at follow up intervals. Low dose of radioactive Iodine-131 was found as effective as high dose in thyroid remnant ablation of PTC patients.

show abstract

Section: Discussionmentioning

confidence: 95%

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience

et al. 2021

View full text Add to dashboard Cite

show abstract

“…8 Additionally, some authors have concluded that a low dose of radioiodine is as effective as a high dose of radioiodine for ablation of the thyroid remnant after total thyroidectomy for low-risk DTC. [33][34][35] Several factors are associated with unsuccessful RAI ablation, but in most studies, only lymph node recurrence was a significant factor. 36 In this research, in addition to lymph node recurrence, we found persistent positive Tg value and some false positive I-131 imaging, like thyroglossal duct cyst and thymoma uptaking I-131, all led to multiple RAI.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma

Gray

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

Objectives Follicular variant papillary thyroid carcinoma (FVPTC) is treated similarly to classical variant papillary thyroid carcinoma (cPTC). However, FVPTC has unique tumour features and behaviours. We investigated whether a low dose of radioiodine was as effective as a high dose for remnant ablation in patients with FVPTC and evaluated the recurrence of low-intermediate risk FVPTC. Methods Data from cPTC and FVPTC patients treated with I-131 from 2004 to 2014 were reviewed. Demographics, tumour behaviour, lymph node metastasis, and local recurrence data were compared between FVPTC and cPTC patients. Then, low-intermediate risk FVPTC patients were divided into low, intermediate, and high I-131 dose groups, and postoperative I-131 activities were analysed to evaluate the effectiveness of I-131 therapy for thyroid remnant ablation. Results In total, 799 cases of FVPTC (n = 168) and cPTC (n = 631) treated with I-131 were identified. Patients with FVPTC had a larger primary nodule size than cPTC, but lymph node metastases and local recurrence were more prevalent in cPTC than in FVPTC. For the low-, intermediate-, and high-dose groups, success rates of ablation did not differ (82.0%, 80%, and 81.3%, respectively). Conclusion FVPTC differs from cPTC in behaviour. Low-dose ablation may be sufficient in FVPTC patients with low-intermediate disease risk.

show abstract

“…Ablation success rates after the first dose were 78.2% in the low-dosage group and 73.3% in the high-dose group (P =0.36). Final success was 97.6% of those given the low dose and 98.9% of those given the high dose (P =0.54) (9) .…”

Section: 025mentioning

confidence: 95%

Impact of Ablative Low Dose Radio-Active Iodine after Thyroidectomy in Low–Risk Differentiated Thyroid Cancer

Elrefai

Allam²,

El-zahi³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Thyroid cancer (TC) is the most frequent endocrine cancer, comprising for 3-4% of all tumors. Objective: The aim of the current study was to assess the efficacy, safety, and disease-free survival of low-dose RAI (iodine-131) in patients with low-risk differentiated thyroid cancer (DTC) who had low-dose RAI for thyroid residual ablation after full or near-total thyroidectomy. Patients and methods: Between January 2013 and July 2019, 35 patients with low-risk well-differentiated thyroid cancer were investigated by the Clinical Oncology and Nuclear Department at Mansoura University Hospitals. Results: The majority of our patients (94.3%) were females. A total of 34 (97.1%) patients had papillary thyroid cancer and 1 (2.8 %) patient had follicular thyroid carcinoma. All patients were Stage I; 13 (37.1%) patients were T1, and 22 (62.9%) patients were T2 thyroid carcinoma. All patients had pathologically negative lymph nodes and 8 (22.8%) patients had complete thyroidectomy with block neck dissection (BND), whereas the remaining 27 (77.1%) patients had total thyroidectomy without BND. Conclusion: Low-dose radioactive iodine ablation following surgery is an effective approach for treating low-risk DTC, because it decreases the side effects while preserving a good quality of life.

show abstract

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer

Cited by 7 publications

References 24 publications

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience

Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma

Impact of Ablative Low Dose Radio-Active Iodine after Thyroidectomy in Low–Risk Differentiated Thyroid Cancer

Contact Info

Product

Resources

About